<DOC>
	<DOCNO>NCT02930317</DOCNO>
	<brief_summary>Efficacy , Safety Pharmacokinetics Study rFVIII Chinese subject Hemophilia A.To ass efficacy safety rFVIII administer treatment on-demand therapy adult adolescent ( 12-65 year ) patient severe moderately severe Hemophilia A . To determine pharmacokinetic ( PK ) parameter rFVIII .</brief_summary>
	<brief_title>Evaluate Efficacy Safety Recombinant Factor VIII （rFVIII）Treatment Severe Moderately Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Diagnosis hemophilia A Age 12 Years 65 Years，Diagnosis severe （defined &lt; 1 % FVIII : C document medical records） moderately severe（defined 1 % 5 % FVIII : C document medical records） hemophilia A .Subjects who（Age 18 Years 65 Years） receive currently receive FVIII product ( plasmaderived and/or recombinant FVIII ) &gt; 150 exposure day ( EDs ) FVIII product；The Callan ( Age 12 Years 17 ) receive FVIII product &gt; 50 EDs FVIII product . Subjects without past history , current factor VIII inhibitor . For laboratorybased assessment , Bethesda inhibitor titer Lower laboratory 's normal range ＜0.6 BU/mL ( BU : Bethesda Units ) . Liver kidney function accordance standard Subjects childbearing potential agree use utilize adequate method contraception throughout treatment least 28 day study stop Evidence personally legally acceptable representative ( legally acceptable representative applicable Callan subject ) sign date informed consent document indicate subject inform pertinent aspect study The part one subject subject willing able comply schedule visit , treatment plan , laboratory test , study procedure ; Subjects must non bleed state administration rFVIII Day 1 ; Subjects receive infusion FVIII product least 3 day ( least 72 hour ) administration rFVIII Day 1 Current FVIII inhibitor history FVIII inhibitor ( ＞0.6 BU/mL ) Diagnosed bleed disorder addition hemophilia Documented Human Immunodeficiency Virus ( HIV ) Subjects anticipate elective surgery invasive procedure within 1 month follow study entry Treatment immunomodulatory within 30 day 5 half life precede Day 1 , whichever long Subjects know hypersensitivity active substance excipients rFVIII . Subjects know hypersensitivity Chinese Human embryonic kidney cell proteins Subjects severe anemia require blood transfusion Subjects significant hepatic renal impairment ( alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 5 x ULN , total bilirubin &gt; 2 x ULN serum creatinine &gt; 2 x ULN ) , prothrombin time &gt; 1.5 x ULN , platelet count &lt; 80,000 μL . History sensitivity heparin heparin induce thrombocytopenia others thrombocytopenia Patients heart surgery history require anticoagulation therapy ; Subjects severe heart disease , include myocardial infarction heart failure Grade 3 high ( NYHA Classification ) Blood pressure unable control ideally ( systolic pressure＞150 mmHg，diastolic pressure＞90 mmHg ) Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>